Escitalopram in the treatment of adolescent depression

A randomized placebo-controlled multisite trial

Graham J. Emslie, Daniel Ventura, Andrew Korotzer, Stavros Tourkodimitris

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

OBJECTIVE:: This article presents the results from a prospective, randomized, double-blind, placebo-controlled trial of escitalopram in adolescent patients with major depressive disorder. METHOD:: Male and female adolescents (aged 12-17 years) with DSM-IV-defined major depressive disorder were randomly assigned to 8 weeks of double-blind treatment with escitalopram 10 to 20 mg/day (n = 155) or placebo (n = 157). The primary efficacy parameter was change from baseline to week 8 in Children's Depression Rating Scale-Revised (CDRS-R) score using the last observation carried forward approach. RESULTS:: A total of 83% patients (259/312) completed 8 weeks of double-blind treatment. Mean CDRS-R score at baseline was 57.6 for escitalopram and 56.0 for placebo. Significant improvement was seen in the escitalopram group relative to the placebo group at endpoint in CDRS-R score (-22.1 versus -18.8, p =.022; last observation carried forward). Adverse events occurring in at least 10% of escitalopram patients were headache, menstrual cramps, insomnia, and nausea; only influenza-like symptoms occurred in at least 5% of escitalopram patients and at least twice the incidence of placebo (7.1% versus 3.2%). Discontinuation rates due to adverse events were 2.6% for escitalopram and 0.6% for placebo. Serious adverse events were reported by 2.6% and 1.3% of escitalopram and placebo patients, respectively, and incidence of suicidality was similar for both groups. CONCLUSIONS:: In this study, escitalopram was effective and well tolerated in the treatment of depressed adolescents.

Original languageEnglish (US)
Pages (from-to)721-729
Number of pages9
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume48
Issue number7
DOIs
StatePublished - Jul 2009

Fingerprint

Citalopram
Placebos
Depression
Therapeutics
Major Depressive Disorder
Observation
Muscle Cramp
Incidence
Sleep Initiation and Maintenance Disorders
Diagnostic and Statistical Manual of Mental Disorders
Nausea
Human Influenza
Headache

Keywords

  • Depression
  • SSRI
  • Treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

Escitalopram in the treatment of adolescent depression : A randomized placebo-controlled multisite trial. / Emslie, Graham J.; Ventura, Daniel; Korotzer, Andrew; Tourkodimitris, Stavros.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 48, No. 7, 07.2009, p. 721-729.

Research output: Contribution to journalArticle

@article{fdd2c0dfbd0a47caafe401311d097da6,
title = "Escitalopram in the treatment of adolescent depression: A randomized placebo-controlled multisite trial",
abstract = "OBJECTIVE:: This article presents the results from a prospective, randomized, double-blind, placebo-controlled trial of escitalopram in adolescent patients with major depressive disorder. METHOD:: Male and female adolescents (aged 12-17 years) with DSM-IV-defined major depressive disorder were randomly assigned to 8 weeks of double-blind treatment with escitalopram 10 to 20 mg/day (n = 155) or placebo (n = 157). The primary efficacy parameter was change from baseline to week 8 in Children's Depression Rating Scale-Revised (CDRS-R) score using the last observation carried forward approach. RESULTS:: A total of 83{\%} patients (259/312) completed 8 weeks of double-blind treatment. Mean CDRS-R score at baseline was 57.6 for escitalopram and 56.0 for placebo. Significant improvement was seen in the escitalopram group relative to the placebo group at endpoint in CDRS-R score (-22.1 versus -18.8, p =.022; last observation carried forward). Adverse events occurring in at least 10{\%} of escitalopram patients were headache, menstrual cramps, insomnia, and nausea; only influenza-like symptoms occurred in at least 5{\%} of escitalopram patients and at least twice the incidence of placebo (7.1{\%} versus 3.2{\%}). Discontinuation rates due to adverse events were 2.6{\%} for escitalopram and 0.6{\%} for placebo. Serious adverse events were reported by 2.6{\%} and 1.3{\%} of escitalopram and placebo patients, respectively, and incidence of suicidality was similar for both groups. CONCLUSIONS:: In this study, escitalopram was effective and well tolerated in the treatment of depressed adolescents.",
keywords = "Depression, SSRI, Treatment",
author = "Emslie, {Graham J.} and Daniel Ventura and Andrew Korotzer and Stavros Tourkodimitris",
year = "2009",
month = "7",
doi = "10.1097/CHI.0b013e3181a2b304",
language = "English (US)",
volume = "48",
pages = "721--729",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - Escitalopram in the treatment of adolescent depression

T2 - A randomized placebo-controlled multisite trial

AU - Emslie, Graham J.

AU - Ventura, Daniel

AU - Korotzer, Andrew

AU - Tourkodimitris, Stavros

PY - 2009/7

Y1 - 2009/7

N2 - OBJECTIVE:: This article presents the results from a prospective, randomized, double-blind, placebo-controlled trial of escitalopram in adolescent patients with major depressive disorder. METHOD:: Male and female adolescents (aged 12-17 years) with DSM-IV-defined major depressive disorder were randomly assigned to 8 weeks of double-blind treatment with escitalopram 10 to 20 mg/day (n = 155) or placebo (n = 157). The primary efficacy parameter was change from baseline to week 8 in Children's Depression Rating Scale-Revised (CDRS-R) score using the last observation carried forward approach. RESULTS:: A total of 83% patients (259/312) completed 8 weeks of double-blind treatment. Mean CDRS-R score at baseline was 57.6 for escitalopram and 56.0 for placebo. Significant improvement was seen in the escitalopram group relative to the placebo group at endpoint in CDRS-R score (-22.1 versus -18.8, p =.022; last observation carried forward). Adverse events occurring in at least 10% of escitalopram patients were headache, menstrual cramps, insomnia, and nausea; only influenza-like symptoms occurred in at least 5% of escitalopram patients and at least twice the incidence of placebo (7.1% versus 3.2%). Discontinuation rates due to adverse events were 2.6% for escitalopram and 0.6% for placebo. Serious adverse events were reported by 2.6% and 1.3% of escitalopram and placebo patients, respectively, and incidence of suicidality was similar for both groups. CONCLUSIONS:: In this study, escitalopram was effective and well tolerated in the treatment of depressed adolescents.

AB - OBJECTIVE:: This article presents the results from a prospective, randomized, double-blind, placebo-controlled trial of escitalopram in adolescent patients with major depressive disorder. METHOD:: Male and female adolescents (aged 12-17 years) with DSM-IV-defined major depressive disorder were randomly assigned to 8 weeks of double-blind treatment with escitalopram 10 to 20 mg/day (n = 155) or placebo (n = 157). The primary efficacy parameter was change from baseline to week 8 in Children's Depression Rating Scale-Revised (CDRS-R) score using the last observation carried forward approach. RESULTS:: A total of 83% patients (259/312) completed 8 weeks of double-blind treatment. Mean CDRS-R score at baseline was 57.6 for escitalopram and 56.0 for placebo. Significant improvement was seen in the escitalopram group relative to the placebo group at endpoint in CDRS-R score (-22.1 versus -18.8, p =.022; last observation carried forward). Adverse events occurring in at least 10% of escitalopram patients were headache, menstrual cramps, insomnia, and nausea; only influenza-like symptoms occurred in at least 5% of escitalopram patients and at least twice the incidence of placebo (7.1% versus 3.2%). Discontinuation rates due to adverse events were 2.6% for escitalopram and 0.6% for placebo. Serious adverse events were reported by 2.6% and 1.3% of escitalopram and placebo patients, respectively, and incidence of suicidality was similar for both groups. CONCLUSIONS:: In this study, escitalopram was effective and well tolerated in the treatment of depressed adolescents.

KW - Depression

KW - SSRI

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=68749084664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68749084664&partnerID=8YFLogxK

U2 - 10.1097/CHI.0b013e3181a2b304

DO - 10.1097/CHI.0b013e3181a2b304

M3 - Article

VL - 48

SP - 721

EP - 729

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 7

ER -